Capital Performance Advisors LLP Apellis Pharmaceuticals, Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 1,944 shares of APLS stock, worth $54,393. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,944Holding current value
$54,393% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
114MCall Options Held
5.21MPut Options Held
691K-
Wellington Management Group LLP Boston, MA16.4MShares$459 Million0.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$325 Million15.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$311 Million5.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$274 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$162 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.07B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...